Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer

Launched by KUIRONG JIANG · Apr 8, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new combination treatment for pancreatic cancer that involves a medication called irinotecan liposome, combined with two other drugs, oxaliplatin and tegafur. The goal is to see how well this treatment works and how safe it is for patients who have already had surgery to remove their cancer. The trial is currently looking for participants who have had a specific type of pancreatic cancer and are in relatively good health.

To be eligible for this trial, participants should be between the ages of 65 and 74, have a good performance status (meaning they can carry out daily activities with minimal assistance), and should have a life expectancy of at least six months. They should also be able to eat normally and not have severe digestive issues. If someone decides to join the trial, they can expect regular check-ups and monitoring throughout the treatment, helping researchers understand how well the new therapy works for pancreatic cancer patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. ECOG performance status 0 or 1.
• • 2. Histologically confirmed resected ductal pancreatic adenocarcinoma with macroscopic complete resection (R0 and R1).
• • 3. ECOG performance status 0 or 1.
• • 4. Life expectancy of greater than or equal to 6 months.
• • 5. Able and willing to provide a written informed consent.
• Exclusion Criteria:
• • 1. Patients who cannot eat orally and have gastric emptying disorder after surgery;
• • 2. Patients with moderate diarrhea: diarrhea ≥4 times per day; the moderate and severe effluents from stoma increased; Or diarrhea that limits activities of daily living;
• • 3. Patients who cannot eat orally and have gastric emptying disorder after surgery;
• • 4. Patients who cannot eat orally and have gastric emptying disorder after surgery;